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nvestigations and pre-clinical and clinical safety studies, may help
o make informed decisions in clinical practice.
Methods: Pre-clinical toxicology and clinical safety assess-
ents, both within the context of controlled clinical trials and
ost-marketing surveillance, are conducted for all licensed vac-
ines. In addition pre-clinical adjuvant MoA studies provide
dditional information regarding the safety proﬁle of novel adju-
anted vaccines. Our discussion will focus on the added support
hat MoA studies bring to the safety evaluation of adjuvanted vac-
ines. As an example of MoA and safety data we will use the results
f studies with the AS04-adjuvanted L1/16&18 HPV vaccine.
Results: The preclinical toxicology package of the AS04-
djuvanted L1/16&18 HPV vaccine has not shown treatment-
elated toxicologyﬁndings other than local injection site inﬂamma-
ion. MoA data showed that AS04 induced a transient and localised
ctivation of innate cells at the injection site and in the local drain-
ng lymph nodes, with no systemic impact or direct effect on T
ells and B-cellls. Clinical safety evaluation and follow-up in a trial
etting have shown no clinically relevant differences compared
ith control groups other than reactogenicity, mostly at local level,
onsistent with ﬁndings from preclinical data and MoA studies.
inally, with more than 25 million doses distributed worldwide,
ost-licensure safety evaluations have shown adverse events con-
istent with what has been observed in the clinical development
rogram, with most commonly reported events being local site
eactions of short duration (2-3 days).
Conclusion:Regulatory authorities require rigorouspre-clinical
nd clinical safety data to determine the beneﬁt/risk proﬁle of new
accines. Post-licensure, a continuous pharmacovigilance system
s in place to further assess vaccine safety. Research studying the
echanism of action of an adjuvanted vaccine can help to further
nvestigate the vaccine’s safety proﬁle.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.1008
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Background: The rates of positive tuberculin skin test reactions
nd BCG scarring after BCG vaccination vary between studies and
opulations. Tuberculin reactivity and BCG scarring may be related
o better child survival in low-income countries.
This studywasperformedtoassess the reaction to the tuberculin
kin test and the development of the BCG scar in a cohort of healthy
ewborns.
Methods: We performed the tuberculin test with Puriﬁed pro-
ein derivative (PPD) and the BCG scar in 794 infants 3months after
accination at birth in Arak, Iran.fectious Diseases 16S (2012) e158–e316
Results: Of all children 413 were female (52%). Response to
the tuberculin test was negative in 39%, doubtful in 55% and posi-
tive in 6%. In 96% of cases B.C.G scar was ≥3mm in diameter. The
average size of the reaction to PPD in those with a BCG scar was
greater than those without a scar in all the children in our study,
(p-value <0.001).
Conclusion: In the present study about 96% of infants had a
successful response to BCG vaccination while 4% did not develop a
scar. In some countries repeat vaccination is universal; in others it
is based on either tuberculin skin testing or the absence of a typical
scar. Since the absence of development of the scar does not always
signify a lack of response to the BCG, therefore it is better to do fur-
ther immunological tests to detect a reaction to the vaccine before
deciding to revaccinate these children.
http://dx.doi.org/10.1016/j.ijid.2012.05.1009
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Background: Propolis is a natural resinous hive product, col-
lected by honey bees from plants and mixes with their wax.
Regarding to its pharmacological activities and adjuvants prop-
erty in vaccine formulations, the effect of propolis extracts on
the humoral and cellular immune responses can be exploited for
the development of effective vaccines. This work evaluated the
adjuvant capacity of an ethanol extract of propolis associated to
recombinant GP63 Leishmania protein.
Methods: Brieﬂy, the propoliswas ground andmacerated for 10
days with an extract solution containing absolute ethanol. Then,
the solvent was evaporated and the resulting dried matter was
dissolved in PBS. 27 male BALB/c mice, allocated into four groups,
were inoculated subcutaneously with 0.1ml of 4 different vaccines
formulates at day 0, 7 and 30. Group 1 to 4 have been injected
with normal saline, 50g recombinant (r) GP63, 50g rGP63 plus
5mgpropolis, and 5mgpropolis, respectively. 30 days after the last
inoculation, splenic mononuclear cells were obtained from spleens
of treated mice by Ficol hypaque gradient and 107 isolated cells
were resuspended in 1ml media supplemented with 10% of bovine
fetal serum. The105 cells plated in a 96 well plate and treated with
rGP63. After 4 days, the supernatant was assayed for the content of
IL-4 and IFN- by ELISA methods.
Results: The level of the IL-4 in the Propolis plus rGP63
group was signiﬁcantly higher than the control and rGP63 groups
(P =0.002, P =0.001, respectively). Based on the level of IFN-, no
signiﬁcant differences were observed between propolis plus rGP63
and other treated group.
